Strimvelis® (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase [ADA] cDNA sequence): first case of lymphoid T cell leukaemia after insertional oncogenesis

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Medicine name
Strimvelis
Active substance
autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells
Therapeutic area (MeSH)
Severe Combined Immunodeficiency
Procedure number
EMEA/H/C/003854/R/0029
Regulatory outcome
Maintenance
DHPC type
Adverse event
Human ATC code
L03
Dissemination date
22/03/2021

How useful was this page?

Add your rating